Mixed Connective Tissue Disease
GPTKB entity
Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
autoimmune disease
systemic connective tissue disease |
| gptkbp:affects |
gptkb:skin
gptkb:skeletal_muscle heart lungs gastrointestinal tract kidneys joints muscles |
| gptkbp:complication |
pulmonary hypertension
interstitial lung disease cardiac involvement renal involvement |
| gptkbp:diagnosedBy |
clinical criteria
serological tests anti-U1 RNP antibody test |
| gptkbp:firstDescribed |
1972
Sharp et al. |
| https://www.w3.org/2000/01/rdf-schema#label |
Mixed Connective Tissue Disease
|
| gptkbp:ICD-10_code |
M35.1
|
| gptkbp:overlapsWith |
gptkb:systemic_lupus_erythematosus
gptkb:systemic_sclerosis rheumatoid arthritis polymyositis |
| gptkbp:prevalence |
rare
|
| gptkbp:prognosis |
variable
|
| gptkbp:riskFactor |
genetic predisposition
female sex |
| gptkbp:signature |
gptkb:anemia
thrombocytopenia leukopenia elevated ESR high anti-U1 RNP antibodies positive ANA |
| gptkbp:symptom |
gptkb:Raynaud's_phenomenon
fever fatigue arthritis muscle weakness pericarditis pulmonary hypertension pleuritis skin changes esophageal dysmotility swollen hands myositis |
| gptkbp:treatment |
gptkb:mycophenolate_mofetil
gptkb:methotrexate physical therapy azathioprine corticosteroids immunosuppressive drugs hydroxychloroquine |
| gptkbp:bfsParent |
gptkb:MCTD
|
| gptkbp:bfsLayer |
8
|